The company said that the startup based in Los Angeles for male contraceptive injections to prevent sperm movement has raised $ 200,000 with new financing.
NEXT LIFE SCIENCES stated that injecting cash from male contraceptive initiatives (MCI) will continue to fund the development of products called PLAN A.
MCI, the largest non -profit organization that focuses on male contraception, was awarded two -year subsidies in 2024.
After thoroughly examining the company's progress, the MCI Research Committee unanimously approved the second year of installments to $ 200,000, bringing the total subsidy funds to $ 400,000 to plan A.
The updated support will be conducted in the United States and Canada in the latter half of the year, preparing for Plan A clinical trials in Australia in early 2025.
DARLENE WALLEY, CEO of Next Life Science, has expressed thanks to the MCI commitment.
“Our goal is to bring this innovative contraceptive technology to the market and provide men with long -term reversible family planning options,” Wally.
“This further investment from the MCI accelerates the progress of clinical trials and realizes plans.”
For decades, blood vessels and condoms were the only widespread contraceptive option for men.
NEXT LIFE SCIENCES aims to change it with Plan A. This is a non -invasive procedure, including injecting hydrogel into Vas Deference, a tube that transports sperm.
Gel forms a barrier of a semi -solid body that filters sperm from semen and temporarily sterilizes individuals.
The company claims that this procedure is effective for up to 10 years.
According to NEXT's founder LR Fox, the process is designed to be “quick, safe and simple.”
In order to reverse the procedure, another injection of sodium bicarbonate is included at this time, which dissolves the hydrogel to restore fertility.
“It's all juice, and there's no species,” Fox told reporters and emphasized the possibility of a plan A to transform men's contraception.
In particular, among men between the ages of 18 and 45, who have a dedicated relationship but are not ready to have children, their interest in contraceptives is increasing rapidly.
Fox pointed out that condoms are not always reliable to prevent pregnancy, and quoted research indicating that many women have reported that they have reduced their sexual satisfaction when using their partners. 。
“The demand we are looking at is from a young expert in a dedicated relationship,” he added.
Last year, Contraline, a biotechnology company based in Virginia, reported 99 % of the effectiveness of ADAM, ADAM, a male contraceptive that is said to be “IUD for men.” 。
Plan A is ready to enter a rapidly evolving market as men are interested in contraception.
FOX emphasizes the importance of fairness in contraceptive responsibility beyond the effectiveness.
“load [of contraception] He stated that the choice of contraceptive methods for many women, including contraceptives and hormonal treatments, would fall straight to women. ”
The purpose is to provide a safer and more balanced approach to regenerative health by providing men's reversible and long -term alternatives.
The demand for planning A is clear.
NEXT LIFE SCIENCES started a list of advanced occupations and received thousands of answers from a man who is eager to access the treatment first when available.
The FOX presumed the approval of regulatory agencies, including the Food and Pharmaceutical Bureau (FDA), and that plan A could enter the market within two years.
The company has not disclosed the cost of the procedure yet, but FOX guarantees that accessibility is a priority.
“Everyone who needs plan A will acquire plan A,” he said, emphasizing a wide range of needs for safe and effective male contraception.
With the continuous financing of the MCI and the growing public interest, Next Life Sciences is promoting clinical trials and approval of regulatory authorities with the aim of redefining male contraceptive landscapes in the near future. 。
